NewAmsterdam Pharma Company N.V. last reported quarterly results on Aug 5, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $3.7 million (-80.7% year over year) and diluted EPS of -$0.52. It usually reports 9–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 4, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 5, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 9–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
4
-80.7%
|
-64
-269.4%
|
-0.52
-246.7%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
3
+2.1%
|
-48
-22.6%
|
-0.40
-17.6%
|
|
Jan 9, 2026
9 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
-99.7%
|
-75
+18.7%
|
-0.62
+32.7%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-98.8%
|
-72
-332.5%
|
-0.61
-238.9%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
19
+740.1%
|
-17
+55.5%
|
-0.15
+63.4%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3
+112.6%
|
-40
+57.8%
|
-0.34
+67.9%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
13
|
-92
|
-0.93
|
|
Nov 6, 2024
37 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NAMS (Nasdaq), NAMSW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Netherlands
- Headquarters
- Narrden, Netherlands
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1936258
- Former names
- NewAmsterdam Pharma Co B.V. (until Nov 22, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.